Mustang Bio, Inc.Announces Pricing of Public Offering to Advance Cell and Gene Therapies
Worcester, Mass.-based biopharmaceutical company Mustang Bio, Inc.made a significant announcement today regarding a public offering aimed at accelerating the development of potential cures for difficult-to-treat cancers and rare genetic diseases.The company, listed on Nasdaq as MBIO, revealed the pricing of 16,877,638 shares of its common stock, along with accompanying warrants, at a public offering price of $0.237 per share.
Mustang Bio, Inc.is a clinical-stage biopharmaceutical company dedicated to translating the latest advancements in cell and gene therapies into transformative solutions for patients facing challenging medical conditions.With a focus on leveraging innovative technologies and scientific expertise, Mustang Bio, Inc.is committed to pushing the boundaries of medical research and treatment.
The public offering, which includes Series A-1, A-2, and A-3 warrants to purchase additional shares of common stock, is projected to close on or around May 2, 2024, pending the fulfillment of customary closing conditions.The warrants, offering an exercise price of $0.237 per share, are designed to provide investors with the opportunity to participate in the future growth and success of Mustang Bio, Inc.
Investors and stakeholders in the biopharmaceutical industry are eagerly watching the progress of Mustang Bio, Inc.as it continues to develop groundbreaking therapies that have the potential to revolutionize the treatment of cancer and genetic diseases.The company’s dedication to advancing cell and gene therapies underscores its commitment to improving patient outcomes and addressing unmet medical needs.
As Mustang Bio, Inc.moves forward with its public offering, the company remains focused on driving innovation, fostering collaboration with industry partners, and ultimately delivering life-changing therapies to patients in need.With an unwavering dedication to scientific excellence and patient-centric care, Mustang Bio, Inc.is poised to make a lasting impact on the field of biopharmaceuticals.
Comments